Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ACAMPROSATE CALCIUM

All products: Limited Use (codes 531)

Campral · DIN 02293269 · 333mg · DR tablet

Limited Use — Reason for Use code 531 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 531 required
Write on scriptLU code 531 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 531
Reason for Use code 531 For the treatment of alcohol use disorder in patients who: - Meet clinical criteria for alcohol use disorder; and - Express a commitment to abstain from alcohol; and - Have been abstinent from alcohol for at least 3 days prior to starting acamprosate; and - Have confirmed participation in counselling and treatment for alcohol use disorder* * An individualized treatment plan will have one or more of the following components: Counselling and follow-up with the patient's family physician, addiction physician, or psychiatrist; self-help groups such as Alcoholics Anonymous; and outpatient, day, or inpatient psychosocial rehabilitation programs. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Campral · DIN 02293269 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2018-06-29 Health Canada: Marketed since 2010-05-28 · brand CAMPRAL · ATC N07BB03 ACAMPROSATE · form Tablet (delayed-release) · route Oral · ingredients ACAMPROSATE CALCIUM 333 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Campral: Formulary list price $1.0195/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.0195 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77863 · Verify on the e-Formulary ↗ (DIN 02293269)

Source record
DIN 02293269: Campral Raw flags: sec12=Y, sec3=Y Item: 289200029; group id 533; item number 1442; lccId 00305; manufacturer id MYL Source form: DR Tab; strength: 333mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.0195; ministry $1.0195 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02293269 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77863
Shortage status: resolved shortage (ended 2025-12-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293269
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap

ELETRIPTAN

· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 40mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

MEMANTINE HCL

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 37 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults CAMPRAL® (acamprosate calcium) is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with CAMPRAL® should be part of a comprehensive management program that includes counselling. The efficacy of CAMPRAL® in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning CAMPRAL® treatment. The efficacy of CAMPRAL® in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed. Geriatrics (> 65 years of age): Forty-one of the 4234 patients in double-blind, placebo-controlled, clinical trials of CAMPRAL were 65 years of age or older. There were too few patients in this age group to evaluate any differences in safety or efficacy in geriatric patients compared to younger patients. However, since renal function diminishes in elderly patients and acamprosate is excreted unchanged in urine, acamprosate plasma concentrations are likely to be higher in the elderly population compared to younger adults. (See WARNINGS AND PRECAUTIONS, Specia… https://pdf.hres.ca/dpd_pm/00014184.PDF PM date: not printed or not captured Source product: CAMPRAL; DIN 02293269; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.